Os portfólios farmacêutico e de dispositivos médicos da Johnson & Johnson estão bem posicionados para se beneficiar de populações envelhecidas impulsionando a demanda aumentada por tratamentos de oncologia, imunologia e cirurgia.
A Johnson & Johnson é uma ação blue chip quintessencial com mais de 130 anos de histórico operacional, uma classificação de crédito AAA mantida por muito poucas corporações, e um negócio de saúde diversificado que proporciona estabilidade através de praticamente qualquer ciclo econômico.
A Johnson & Johnson é um gigante da saúde com mais de 60 anos consecutivos de aumentos de dividendos, ancorada por franquias farmacêuticas e de dispositivos médicos líderes em mercados globais.
A Johnson & Johnson é uma Dividend King com mais de 60 anos consecutivos de aumentos de dividendos anuais, apoiada pelos fluxos de caixa estáveis e resistentes à recessão de seus negócios farmacêuticos e de dispositivos médicos. Seu longo histórico de crescimento de dividendos confiável a torna uma ação de dividendo de primeira qualidade para investidores que buscam renda estável do setor de saúde.
Data updated Feb 15 · Source: Twelve Data
Johnson & Johnson remains one of the most dependable names in healthcare investing. Following its Kenvue consumer health spinoff, JNJ is now a focused pharmaceutical and MedTech company, better positioned to capitalize on aging demographics through oncology, immunology, and surgical innovations.
The stock has surged nearly 57% over the past year, now trading near its 52-week high of $246.35 and well above its 50-day moving average. This rally has stretched the P/E ratio to 32.37"elevated relative to historical norms"raising valuation concerns for new entrants. EPS of $7.52 reflects solid but not exceptional earnings power.
As a Dividend Aristocrat with 60+ consecutive years of increases, JNJ's income reliability is unmatched, though the current yield has compressed due to price appreciation. The pharmaceutical pipeline, including Darzalex and Tremfya, provides meaningful growth catalysts, while MedTech benefits from procedure volume recovery.
Key risks include ongoing talc litigation liabilities, patent cliffs on major drugs, and the premium valuation. The bull case centers on pipeline execution, demographic tailwinds, and defensive positioning during economic uncertainty. A strong core holding, though dollar-cost averaging may be prudent at current levels.
Johnson & Johnson remains a definitive blue-chip holding, recently demonstrating robust momentum as it trades near its 52-week high of $240.94. Following its strategic restructuring to focus on high-growth pharmaceutical and MedTech segments, the stock has surged well above its 50-day moving average. However, the current valuation warrants caution; at a P/E ratio of 31.70, JNJ is trading at a significant premium to its historical range, suggesting that optimistic growth expectations are already priced in. While the company's legendary status as a Dividend King continues to attract income investors seeking stability, the stretched multiple may limit near-term upside. JNJ represents a high-quality defensive play with a fortress balance sheet, but value-conscious investors might prefer to wait for a pullback before adding to positions.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
Todo trader tem uma estratégia que parece ótima em sua cabeça. Backtesting é como você descobre se ela realmente funciona. Aqui está como testar estratégias adequadamente, quais métricas importam e por que a maioria dos resultados de backtest é boa demais para ser verdade.
Powered by Rexiew